Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2016-11-21 Earnings Release
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Earnings Release 2016
Earnings Release Classification · 99% confidence The document is a 'Company Announcement' from Genmab A/S dated November 21, 2016. It primarily announces the U.S. FDA approval of DARZALEX in combination therapies for multiple myeloma and simultaneously updates the company's 2016 financial guidance based on associated milestone payments (USD 65 million). The text includes detailed financial outlook tables (Revenue, Operating Income, Cash Position) and extensive clinical trial data (CASTOR and POLLUX studies). This structure—an announcement of a significant event (FDA approval/milestone) coupled with an immediate revision of financial projections—is characteristic of an Earnings Release (ER) or a major corporate event announcement that impacts financial guidance. Since it is an announcement of financial results/guidance update rather than the full, detailed quarterly/annual report (10-K or IR), 'Earnings Release' (ER) is the most appropriate classification. It is not a Call Transcript (CT) or a formal Investor Presentation (IP), but a press release detailing financial impact. FY 2016
2016-11-21 English
Director's Dealing 2016
Director's Dealing Classification · 100% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and explicitly states it is reporting transactions made by a person discharging managerial responsibilities (PDMR) under Article 19 of the Market Abuse Regulation (MAR). The content details the name of the executive (Jan van de Winkel, CEO), the nature of the transaction ('Salg af aktier' - Sale of shares), the date (2016-11-11), and the price/quantity. This structure perfectly matches the definition of insider trading reports, which in the provided list corresponds to Director's Dealing (DIRS). Although it is a regulatory announcement, DIRS is a more specific category than the general RNS.
2016-11-11 Danish
Director's Dealing 2016
Director's Dealing Classification · 100% confidence The document is titled "Company Announcement" and explicitly details a transaction involving a person discharging managerial responsibilities (President & Chief Executive Officer) regarding the sale of company shares. This structure, referencing Article 19 of Regulation No. 596/2014 (Market Abuse Regulation), is the standard format for reporting insider trading or director's dealings in European markets. This directly matches the definition for Director's Dealing (DIRS).
2016-11-11 English
Ledende medarbejderes og deres nærtståendes transaktioner med aktier og tilknyttede værdipapirer i Genmab A/S
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction in shares by a person with managerial responsibilities (the CEO, Jan van de Winkel) at Genmab A/S. It explicitly details the sale of shares, including the price, quantity, and date, in accordance with the EU Market Abuse Regulation (MAR). This fits the definition of a Director's Dealing (DIRS) report.
2016-11-11 English
Ledende medarbejderes og deres nærtståendes transaktioner med aktier og tilknyttede værdipapirer i Genmab A/S
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by a person discharging managerial responsibilities (the CEO, Jan van de Winkel). It explicitly details the sale of shares, the price, the volume, and the date of the transaction, in compliance with the EU Market Abuse Regulation (MAR). This fits the definition of a Director's Dealing (DIRS) filing.
2016-11-11 English
Genmab offentliggør fase III studie med daratumumab i kombination med carfilzomib til behandling af myelomatose
Regulatory Filings Classification · 14% confidence The document is a corporate press release announcing a new Phase III clinical study collaboration and drug development plans. It contains no financial statements, vote results, management changes, dividends, or regulatory certifications, and is not a shareholder meeting presentation. There is no substantive financial data or investor Q&A. It is a general corporate update/announcement, fitting the catch-all category for miscellaneous regulatory communications. Therefore, it should be classified as Regulatory Filings (RNS).
2016-11-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.